HSE approves Skyclarys for Friedreich's ataxia; patient advocates celebrate landmark decision

The HSE has made a landmark decision to fund Skyclarys (omaveloxolone) for Friedreich's ataxia, following sustained advocacy from patients like Isabella Travers. The approval marks a significant policy shift in rare disease drug access in Ireland, though implementation details and patient eligibility remain to be clarified.